Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Agnieszka Rydz has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Eruptive Syringoma—Clinical, Dermoscopic, and Reflectance Confocal Microscopy Features

    by Agnieszka Rydz, Jakub Żółkiewicz, Michał Kunc, Martyna Sławińska, Michał Sobjanek, Roman J. Nowicki, Magdalena Lange

    We present an interesting image of eruptive syringoma confirmed by histopathological assessment in a 37-year-old male who was consulted due to numerous brownish small macules and papules resembling maculopapular cutaneous mastocytosis (MPCM). We show difficulties in diagnosing ES, given its rare occurrence and resemblance to other dermatological disorders. Moreover, we discuss the role of dermoscopy and reflectance confocal microscopy in the differential diagnosis of syringoma.

  • Open Access

    Diffuse Cutaneous Mastocytosis: A Current Understanding of a Rare Disease

    by Agnieszka Rydz, Magdalena Lange, Hanna Ługowska-Umer, Monika Sikorska, Roman J. Nowicki, Cristina Morales-Cabeza, Iván Alvarez-Twose

    Mastocytosis is a heterogeneous disease characterized by the expansion and accumulation of neoplastic mast cells in various tissues. Diffuse cutaneous mastocytosis (DCM) is a rare and most severe form of cutaneous mastocytosis, which typically occurs in childhood. There have been reports of a familial DCM with specific gene mutations, indicating both sporadic and hereditary factors involved in its pathogenesis. DCM is associated with severe MC mediator-related symptoms and an increased risk of anaphylaxis. The diagnosis is based on the appearance of skin lesions, which typically show generalized thickening, erythroderma, blistering dermographism, and a positive Darier’s sign. Recognition, particularly in infants, is challenging due to DCMs resemblance to other bullous skin disorders. Therefore, in unclear cases, a skin biopsy is crucial. Treatment focuses on symptom management, mainly including antihistamines and mast cell stabilizers. In extremely severe cases, systemic steroids, tyrosine kinase inhibitors, phototherapy, or omalizumab may be considered. Patients should be equipped with an adrenaline autoinjector. Herein, we conducted a comprehensive review of literature data on DCM since 1962, which could help to better understand both the management and prognosis of DCM, which depends on the severity of skin lesions, intensity of mediator-related symptoms, presence of anaphylaxis, and treatment response.


  • Open Access

    Current Challenges in the Diagnosis of Pediatric Cutaneous Mastocytosis

    by Hanna Ługowska-Umer, Justyna Czarny, Agnieszka Rydz, Roman J. Nowicki, Magdalena Lange

    Pediatric mastocytosis is mostly a cutaneous disease classified as cutaneous mastocytosis (CM), which is characterized by mast cell (MCs) accumulation in the skin and the absence of extracutaneous involvement. Based on the morphology of skin lesions, CM can be divided into three major forms: maculopapular CM (MPCM), diffuse CM (DCM) and mastocytoma of the skin. A positive Darier’s sign is pathognomonic for all forms of CM. MPCM is the most common form, presenting with red-brown macules or slightly raised papules. Mastocytoma is characterized by solitary or a maximum of three nodular or plaque lesions. DCM is a rare, severe form which presents as erythroderma, pachydermia and blistering in the infantile period of the disease. CM is associated with MC mediator-related symptoms, most commonly including pruritus, flushing, blistering, diarrhea and cramping. Anaphylactic shock occurs rarely, mainly in patients with extensive skin lesions and a significantly elevated serum tryptase level. Childhood-onset MPCM and mastocytoma are usually benign diseases, associated with a tendency for spontaneous regression, while DCM is associated with severe mediator-related symptoms, an increased risk of anaphylaxis and, in some cases, underlying systemic mastocytosis (SM). In contrast to adults, SM is a rare finding in children, most commonly presenting as indolent SM. However, advanced SM sporadically occurs.


  • Open Access

    Hereditary alpha tryptasemia: literature overview on the genetic trait and its clinical manifestations

    by Agnieszka Rydz, Magdalena Lange

    Hereditary Alpha Tryptasemia (HαT) is a genetic condition characterized by an increased number of copies of the TPSAB1 gene, resulting in elevated basal serum tryptase levels and an increased risk of anaphylaxis, especially in individuals with IgE-dependent allergies or systemic mastocytosis. The severity of clinical symptoms can vary and is influenced by the number of extra TPSAB1 gene copies, suggesting a gene-dose effect. Approximately two-thirds of individuals with HαT show minimal or no symptoms. The remaining individuals with HαT may present with Hymenoptera venom allergy, flushing, urticarial/angioedema, irritable bowel syndrome, gastrointestinal reflux, hypermobility, neuropsychiatric symptoms and dysautonomia. Recent studies revealed that α-tryptase which forms complexes with β-tryptase activate protease-activated receptor-2 (PAR2) receptors. Activation of these receptors may lead to hypotension, muscle contraction, inflammation, and trigger neuropeptide secretion, and in consequence, result in mast cell degranulation. This cycle of activation and degranulation may potentially contribute to the development of mast cell activation syndrome (MCAS). Mast cell activation syndromes are defined by systemic, severe and recurrent mast cell activations, usually in the form of anaphylaxis. Hereditary/ familial MCAS is a specific subtype of MCAS, which is associated with HαT. Diagnostic work-up for HαT includes determination of basal serum tryptase level and the presence of additional TPSAB1 gene copies using droplet digital polymerase chain reaction. Further research is needed, to explore the relationship between HαT and MCAS, as well as to determine if there is a distinct form of hereditary MCAS which is independent of HαT. These investigations aim to improve diagnostic approaches and treatment strategies for individuals with HαT, enhancing their management and overall quality of life. Hereditary Alpha Tryptasemia (HαT) is a genetic condition characterized by an increased number of copies of the TPSAB1 gene, resulting in elevated basal serum tryptase levels and an increased risk of anaphylaxis, especially in individuals with IgE-dependent allergies or systemic mastocytosis. The severity of clinical symptoms can vary and is influenced by the number of extra TPSAB1 gene copies, suggesting a gene-dose effect. Approximately two-thirds of individuals with HαT show minimal or no symptoms. The remaining individuals with HαT may present with Hymenoptera venom allergy, flushing, urticarial/angioedema, irritable bowel syndrome, gastrointestinal reflux, hypermobility, neuropsychiatric symptoms and dysautonomia. Recent studies revealed that α-tryptase which forms complexes with β-tryptase activate protease-activated receptor-2 (PAR2) receptors. Activation of these receptors may lead to hypotension, muscle contraction, inflammation, and trigger neuropeptide secretion, and in consequence, result in mast cell degranulation. This cycle of activation and degranulation may potentially contribute to the development of mast cell activation syndrome (MCAS). Mast cell activation syndromes are defined by systemic, severe and recurrent mast cell activations, usually in the form of anaphylaxis. Hereditary/ familial MCAS is a specific subtype of MCAS, which is associated with HαT. Diagnostic work-up for HαT includes determination of basal serum tryptase level and the presence of additional TPSAB1 gene copies using droplet digital polymerase chain reaction. Further research is needed, to explore the relationship between HαT and MCAS, as well as to determine if there is a distinct form of hereditary MCAS which is independent of HαT. These investigations aim to improve diagnostic approaches and treatment strategies for individuals with HαT, enhancing their management and overall quality of life.